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Does Pharmacogenetics Play a Role in the Treatment
of Type II Diabetes Mellitus?
Lucas N VanEmelen, PA-S

Abstract

Statement of the Problem

• Type 2 diabetes mellitus (T2DM) is a disease commonly
presented in the family practice setting. Current therapies
include one or multiple medications. Until recently, providers
have used algorithms and medical expertise to control T2DM.
• Pharmacogenomics is a branch of pharmacology dealing with
genetic variation on a medication response in an individual
patient to discover medication compatibility, efficacy or
toxicity.
• Analysis of genetic factors are still being discovered; however,
this growing field may change the way medications are being
prescribed for diabetes. This analysis investigated if
pharmacogenetics is a useful tool for prescribing diabetic
medications to T2DM patients. It was found that health care
providers will be able to maximize therapy to those currently
taking diabetic medication.
• The goal would be to personalize the treatment of T2DM by
ensuring compatibility of the medication being prescribed.
Although many genes have been implicated in the response to
diabetic medications, the findings indicate that health care
providers can improve the quality of care of patients taking
diabetic medications by choosing the correct diabetic
medication for the individual patient.

• Since diabetes is not currently a curable disease, clinical
guidance suggests the ability to tailor medications to the
patients’ needs may be the best compound the future of
diabetes.
• Developing new medications is a lengthy process. The
development of new medications which can take 10-20 years to
develop and receive approval. Utilizing medications already in
use to detect compatibility to each individual patient is still
being developed.

Discussion

Applicability to Clinical
Practice

• Multiple genes that are associated with the risk of developing
diabetes or the risk of diabetes complications have been
identified by candidate gene analysis and genome wide
scanning.

• Diabetes has increased disabilities and an enormous cost to the
health care system while reducing the quality of life and life
expectancy.
• Strategies for personalized approaches to glycemic management
discussed represents a personalized management approach to
lowering blood glucose concentrations. The recent studies and
advances in genetic and other molecular technologies creates a
strong interest in more personalized approaches to diabetes
management which will be the most effective for the patient.

• Multiple genes associated with the risk of developing diabetes
have been identified by gene analysis and genome scanning.
• Markers together with clinical data, pharmacogenetics and
other methods lead to the consideration of diabetes care being
treated by genetic make-up of a patient.
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Does Pharmacogenetics Play a Role in the Treatment of Type 2
Diabetes Mellitus?

• Pharmacogenetics can lead to the personalized treatment of type
II diabetes.

•
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•

Introduction
Type 2 diabetes mellitus is a worldwide epidemic

• A multifactorial, heterogeneous metabolic disorder
characterized by hyperglycemia and elevated insulin resistance.
• Results from both genetic and environmental factors.
• Multiple genes that are associated with the risk of developing
diabetes
• Patients are often treated with more than one medication.
• Genetic testing could be employed to predict treatment outcome

Pharmacogenetic
• Studies focused on diabetic medications and a role of common
drug-metabolizing enzymes and drug-transporters variants in
therapy outcomes.

• T2DM patients are often treated with more than one drug,
including oral diabetic drugs.
• If genetic testing could be employed to predict treatment
outcome, appropriate measures could be taken to treat T2DM
more efficiently.

Literature Review
Biguanide
• In 2011, Zhou et al. found that common variants near the ataxia
telangiectasia mutated (ATM) are associated with glycemic response to
metformin in type 2 diabetes. Metformin is recommended as a first line
therapy for type 2 diabetes in most international guidelines.
• Becker et al. 2009, examined the genetic variation in the organic cation
transporter that is associated with metformin response in patients with
diabetes mellitus.

• Thiazolinediones
• Aquilante et al. 2013, examined the influence of CYP2C8*2 on the
pharmacokinetics of pioglitazone in healthy African American volunteers.
The data in the study suggested a potential functional significance and
merits further study.

• Known genes that cause diabetes have been reviewed and
genotyping of an individual with diabetes could direct providers
to accurate choices for diabetic therapy

Sulfonylureas

• The genome-wide association studies (GWAS) have facilitated
a substantial and rapid rise in the number of confirmed genetic
susceptibility variants for type 2 diabetes.

• The major allele of this gene is CYP2C9*1.
• There are also two variants with reduced function, CYP2C9 *2 and
CYP2C9*3, which are associated with decreased clearance in the liver with
better effect of this medication

•

•
•

•
•

• The result of Type 2 diabetes is many long-term adverse
consequences. Chronic hyperglycemia results in microvascular
complications such as retinopathy, nephropathy and neuropathy,
and macrovascular complications such as cardiovascular
disease, stroke and peripheral vascular disease.

•
•
•

•
•
•

• The goal of Type 2 diabetes treatment in men and non-pregnant
women is to decrease periods of poor glycemic control and
maintain hemoglobin (HbA1c) levels of less than 7%. Lowering
glucose to near non-diabetic levels in Type 2 diabetes patients
has been shown to reduce the risk of microvascular
complications.

• There are several genes associated with diabetes and
hyperglycemic medications with more studies being published
every day.

• Sulfonylureas are metabolized in the liver by CYP2C9.

• The future of promoting safe and cost-effective individualized
diabetes treatment, pharmacogenomics has a great potential to
complement current efforts to optimize treatment of diabetes
and lead towards its effectiveness and personalized care.

•

•

Meglitinides
• Huang et al. 2010, examined IGF2BP2 variations inﬂuence repaglinide
response and risk of type 2 diabetes in the Chinese population. Patients
with the rs4402960 GT+TT genotypes exhibited an enhanced effect of
repaglinide treatment on postprandial serum insulin compared with GG
genotype subjects.

•

• More evidence and studies will need to be conducted to see if
pharmacogenomics will play a role in the future treatment of
type 2 diabetes mellitus.
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